Goldline Pharmaceutical SME IPO
Goldline Pharmaceutical IPO — date, price band, GMP & allotment 2026
Goldline Pharmaceutical IPO will open from 12 May 2026 to 14 May 2026. Established in 2005, the company is engaged in marketing pharmaceutical products under its “Goldline” brand across segments like general medicine, cardiology, diabetology, pediatrics, and wellness. The company follows an asset-light business model by outsourcing manufacturing to third-party pharma manufacturers while focusing on branding and distribution. Goldline has a strong presence across multiple Indian states, with operations mainly based in Nagpur, Maharashtra.
Stock price
Goldline Pharmaceutical is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 20 September.
- Open 12 May 2026
- Close 14 May 2026
- Allotment 15 May 2026
- Refund/credit 18 May 2026
- Listing 19 May 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 12 to 14 May, 2026 |
|---|---|
| Price Band | ₹41 – ₹43 |
| Face Value | ₹10 |
| Lot Size | 3000 Shares |
| Issue Size | ₹12 Cr |
| Sale Type | Fresh capital only |
| Listing On | BSE SME |
| Registrar | Bigshare Services Private Limited |
| Min Investment | ₹ 2,58,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 3000 shares at the ₹43 cut-off. The SME retail application is a fixed 2 lots; HNI starts at 3.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 6,000 | ₹2,58,000 |
| Retail (max) | 2 | 6,000 | ₹2,58,000 |
| HNI (min) | 3 | 9,000 | ₹3,87,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Asset-light business model reduces manufacturing costs and improves operational scalability significantly.
- 02Diversified pharmaceutical portfolio caters to multiple therapeutic and healthcare treatment segments.
- 03Strong doctor and distributor network supports consistent product demand across regions.
- 04Experienced promoters with pharmaceutical industry knowledge help drive business expansion plans.
Risks · 5
- 01Dependence on third-party manufacturers may impact product quality and timely supply.
- 02Highly competitive pharmaceutical industry can pressure margins and market share growth.
- 03Revenue concentration in domestic markets increases dependence on Indian pharmaceutical demand.
- 04Regulatory changes in healthcare sector may affect operations and product approvals.
- 05Smaller business scale compared to major pharma companies limits competitive advantages currently.
Three years of numbers
All figures in ₹ crore, as reported in the Goldline Pharmaceutical offer document.
| Metric | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
See how this IPO compares — view listing performance of all SME IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Goldline Pharmaceutical RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Goldline Pharmaceutical IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹3.09 |
| P/E Ratio (x) | 13.93 |
| Market Cap at Offer Price (₹ Cr) | ₹30.89 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹43 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹8.90 Cr of the issue is earmarked to named objects.
About the company
The company offers products across general medicine, antibiotics, cardiology, diabetology, gynecology, pediatrics, and wellness categories. Goldline Pharmaceutical mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. This model helps reduce capital expenditure and improve scalability. The company’s operations are mainly based in Nagpur, Maharashtra, with a growing presence across multiple Indian states through its marketing and sales network.
Interested in this IPO? Check the live subscription status or browse all upcoming SME IPOs.
+91 712 2786666
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Cumulative Capital Pvt. Ltd.
3 issues handled (2 mainboard, 1 SME)Best listing: Mehul Telecom (+10.2%). Weakest: Hexagon Nutrition (+7.2%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Goldline Pharmaceutical?
The current Grey Market Premium is ₹15, or 35% over the issue price.
What is the Goldline Pharmaceutical IPO price band?
₹41 to ₹43, on a face value of ₹10.
When is the allotment?
The basis of allotment is 15 May 2026, with listing on 19 May 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Bigshare Services Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every SME and Mainboard issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
